Q1 2027 Anthem Biosciences Ltd Earnings Call Transcript
Key Points
- Anthem Biosciences Ltd (NSE:ANTHEM) reported consolidated revenues of INR418 crores for Q1 FY27, with the CRDMO business contributing 81.5% of the revenues.
- The company achieved an EBITDA margin of 39.6%, reflecting strong operational efficiency.
- Anthem Biosciences Ltd (NSE:ANTHEM) has a robust net cash position of INR1,720 crores as of June 30, 2026.
- The company has a high degree of visibility with 60% of its order book already secured for the year.
- Anthem Biosciences Ltd (NSE:ANTHEM) is expanding its capacity with the construction of Unit 4, expected to be operational by FY28, adding significant production capabilities.
- Q1 FY27 was a softer quarter with a decline in revenue due to timing shifts in customer deliveries.
- Unit 2's capacity utilization was lower at 50% due to recent expansions, indicating underutilization of new capacity.
- The company faces challenges with regulatory approvals for new products, such as the semaglutide API, delaying commercial supply.
- There is a risk of quarterly fluctuations in financial performance due to the nature of the CRDMO business, which depends on customer delivery schedules.
- Anthem Biosciences Ltd (NSE:ANTHEM) anticipates elevated capital expenditures in the coming years due to ongoing expansions, which may impact cash flow.
(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Forum Goshar from Adfactors PR. Thank you, and over to you, Ms. Goshar.
Good morning, everyone. I am Forum Goshar from Adfactors PR Investor Relations. On behalf of Anthem Biosciences Limited, it is my pleasure to welcome you all to the Q1 FY27 earnings conference call.
Joining us on the call today from the management team are Mr. Ajay Bhardwaj, Managing Director and Chief Executive Officer; and Mr. Gawir Baig, Chief Financial Officer.
We will begin today with opening remarks from the management, following which we will open the floor for question-and-answer session.
Before we begin, I would like to remind everyone that certain statements made during this call may be forward-looking in nature. These statements are based on the management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
